News
ABT-199 rebounds in advanced CLL after tackling tumor lysis syndrome
Major finding: The overall response rate was 77% with ABT-199 monotherapy and 84% with the addition of rituximab in relapsed or refractory CLL....
News
Pembrolizumab monotherapy posts 6.75-month PFS in stage IV NSCLC
Key clinical point: Median progression-free survival with the classic chemotherapy doublets ranged from 4.5 months to 5.3 months but reached 6.75...
News
ONO-4059 delivered hit to relapsed/refractory CLL
Key clinical point: ONO-4059 induced responses in most patients with relapsed/refractory CLL, including those with a 17p deletion. Major finding:...
News
Combo olaparib/cediranib slaps down recurrent ovarian cancer
Key clinical point: Combination olaparib plus cediranib may provide an alternative treatment option for women with recurrent, platinum-sensitive...
News
PEI chemotherapy ups survival in sensitive relapsed SCLC, but at a cost
Key clinical point: PEI chemotherapy improves survival in sensitive relapsed SCLC, but at a cost of greater toxicity.Major finding: Median overall...
News
Novel antimetabolite strategy slows progression of deadly mesothelioma
Key clinical point: An antimetabolite strategy that cuts off the supply of arginine to tumors may benefit patients with mesothelioma.Major finding...
News
RADIANT offers mixed results for adjuvant erlotinib in NSCLC
Key clinical point: Adjuvant EGFR TKI therapy may prolong disease progression in NSCLC patients harboring an EGFR mutation.Major finding: Median...
News
Study backs thoracic radiation in extensive small-cell lung cancer
Key clinical point: Thoracic radiotherapy may improve survival when delivered after chemotherapy in extensive-stage lung cancer responding to...
News
Patient satisfaction not always linked to hospital safety, effectiveness
Major finding: In the sample, 62% of high-volume hospitals achieved high patient satisfaction, vs. 38% of low-volume hospitals.
News
De-escalation of ABVD chemotherapy fails in early-stage, favorable Hodgkin’s lymphoma
Major finding: The 5-year FFTF rate was 93.1% with ABVD and 89.2% with AVD (HR, 1.50; 95% confidence interval, 1.00-2.26).Data source: A...
News
De-escalation of ABVD chemotherapy fails in early-stage, favorable Hodgkin’s lymphoma
Major finding: The 5-year FFTF rate was 93.1% with ABVD and 89.2% with AVD (HR, 1.50; 95% confidence interval, 1.00-2.26).Data source: A...
News
Elderly AML patients respond to first-line azacitidine
Key clinical point: Elderly patients with newly diagnosed AML benefit from first-line azacitidine.Major finding: Median overall survival was 10.4...
News
Less frequent zoledronic acid an option in metastatic breast cancer
Major finding: The skeletal-related event rate was 23.2% with zoledronic acid every 12 weeks and 22% with zoledronic acid every 4 weeks (P = .724...
News
TEXT/SOFT provide practice-changing results for premenopausal breast cancer
Key clinical point: Exemestane plus OFS is a new treatment option in the setting of premenopausal hormone-sensitive early breast cancer.Major...
News
PVAG-14 trims chemotherapy toxicity in unfavorable Hodgkin’s lymphoma
Major finding: Any grade 3/4 toxicity was reported in 36.6% of patients and grade 3/4 hematologic toxicity, in 9.8%.Data source: A phase II study...